ESPE Abstracts (2018) 89 P-P1-166

Safety and Effectiveness of Growth Hormone Treatment in Patients with Prader-Willi Syndrome under 2 Years of Age in a Reference Hospital

Raquel Corripioa, Carla Tubaua, Nuria Cahisa, Jacobo Péreza, Josefa Riverab & Elisabeth Gabauc


aPediatric Endocrine Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, UAB, Sabadell, Spain; bPediatric Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, UAB, Sabadell, Spain; cPediatric Genetic Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, UAB, Sabadell, Spain


Introduction: Growth hormone (GH) treatment was approved in 2000 for patients with Prader-Willi syndrome (PWS). The main reason for its use was the improvement in body composition. As a result of 2 fatal episodes, it was decided to initiate it from 2 years of age arbitrarily. Average age of real start: 4-6years. GH per se is not a risk factor for mortality in PWS. The 2013 guideline recommends to star it as soon as possible, preferably under 2 years of age, when obesity is established. The main objective of our study is to test the safety and effectiveness of GH treatment in patients with PWS less than 2 years of age (registered in Clinical Trial Govcode: NCT02205450).

Materials and methods: Longitudinal observational study (EPA-PS) during 2 years of 13 patients with PWS who started treatment with GH under 2 years of age.

Results: We analyzed the data of 13 patients (8 boys and 5 girls) with genetic diagnosis of PWS (64.3% deletion, 35.7% maternal uniparental disomy). The average age of onset of GH was 12.3 months (range of 9-20 months). There were no fatal adverse effects. One patient had a serious adverse effect not attributable to GH (published in Am J Case Rep 2017 Gastric Dilatation). We observed a significant decrease in the subscapular and triceps folds (p <0.0001), an increase in height and a decrease trend in body mass index. Regarding psychomotor level, the median age start walking and speaking was 19.47 and 16.93 months, respectively, (clearly lower in those who started GH <15 months and before of classically described).

Conclusions: GH treatment is safe in PWS patients under two years of age and significantly improves their body composition. Those who started GH before 15 months started to walk sooner.

Article tools

My recent searches

No recent searches.